
Loading, please wait...

Loading, please wait...

Understanding e-cigarette adverse symptoms is essential for clinicians who guide patients through tobacco cessation. A recent secondary analysis of the ESTxENDS trial examined how these symptoms change over six months. Researchers followed 622 participants to determine the safety and tolerability of nicotine freebase e-cigarettes. Notably, the study focused on exclusive e-cigarette users to track specific health outcomes and their impact on long-term abstinence.
The trial revealed that many users experience initial discomfort when switching from tobacco. After the first week, 34% of exclusive users reported dry mouth. Additionally, 23% noted mouth or throat irritation, while 25% experienced a cough. Consequently, these side effects represent common barriers during the early stages of smoking cessation. However, the data suggests that these issues generally resolve with continued use.
By the six-month mark, the proportion of reported symptoms decreased significantly. Dry mouth reports fell to 18%, and cough decreased to 12%. Furthermore, mouth and throat irritation affected only 11% of users. This trend suggests that the body adapts to the aerosolized nicotine or propylene glycol over time. Specifically, continuous use of the device helped resolve dry mouth in a significant number of participants.
Interestingly, the study identified a link between persistent symptoms and smoking re-initiation. Specifically, participants who struggled with mouth or throat irritation were more likely to return to tobacco cigarettes. Therefore, addressing these early side effects is crucial for long-term cessation success. Clinicians should monitor these symptoms closely to prevent patients from relapsing. Moreover, providing clear expectations about initial discomfort may improve patient adherence to cessation programs.
During the first week of use, the most frequent reports include dry mouth, mouth or throat irritation, and coughing. These are often attributed to the propylene glycol and nicotine content in the e-liquid.
Yes, research shows that most symptoms decrease significantly over six months. For instance, the prevalence of cough and mouth irritation halved during the study period for exclusive users.
Notably, the trial found that mouth and throat irritation were primary drivers for smoking re-initiation. Patients experiencing these symptoms may require adjusted devices or e-liquids to remain smoke-free.
Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A secondary analysis of the ESTxENDS trial reveals that e-cigarette side effects diminish over time, though mouth irritation can trigger smoking re-initiati...
8 months ago

Following regulatory scrutiny from FSSAI regarding promotional representations and lean muscle preservation claims, Dr. Reddy's Laboratories and Nestlé Health Science are currently reviewing the branding and marketing strategy for their joint nutritional supplement Celevida GLP+.
Today

A comprehensive scoping review synthesises evidence linking prenatal maternal mental health to long-term offspring neurodevelopment, evaluating neuroendocrine, inflammatory, and epigenetic pathways while highlighting clinical screening and future research priorities.
Today

The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today

A 25-year multi-institutional cohort reveals high recurrence rates in pediatric giant cell tumor of bone, particularly in patients with open physes and bone marrow edema on preoperative MRI. Early surveillance and careful balance between growth plate preservation and tumor clearance are essential.
Today

India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today